

# National Institute of Oncology

[View the current National Institute of Oncology Page on BioPortfolio.com](http://www.bioportfolio.com/biorporate/7377-National+Institute+of+Oncology.html)

(<http://www.bioportfolio.com/biorporate/7377-National+Institute+of+Oncology.html>)

## Contact Details:

**Molecular Biology, Rath Gy. U. 7-9  
Budapest**

Tel:

Fax:

Email:

**H-1525**

**Hungary**

## Recent Publications by National Institute of Oncology:



- [Enhanced 5-fluorouracil cytotoxicity in high cyclooxygenase-2 expressing colorectal cancer cells and xenografts induced by non-steroidal anti-inflammatory drugs via downregulation of dihydropyrimidine dehydrogenase.](#)  
*PURPOSE: To prove that 5-FU cytotoxicity could be increased by combination...*16th October, 2009  
Department of Clinical Research, National Institute of Oncology, Budapest,- Cancer Chemother Pharmacol. 2009 Oct 15. ([DOI Direct Link](#))
- [Choroidal metastasis from tubulopapillary renal cell carcinoma: a case report.](#)  
*Choroidal metastases from renal carcinoma are rare. Most reported cases...*16th October, 2009  
Department of Medical Oncology, National Institute of Oncology Rabat- Cases J. 2009 Jun 29;2:6618. ([DOI Direct Link](#))
- [Co-inhibition of cyclooxygenase-2 and dihydropyrimidine dehydrogenase by non-steroidal anti-inflammatory drugs in tumor cells and xenografts.](#)  
*BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) may be able to...*1st October, 2009  
National Institute of Oncology, Rath Gy. str. 7-9, Budapest H-1122,- Anticancer Res. 2009 Aug;29(8):3095-101.
- [Turning laboratory findings into therapy: a marathon goal that has to be reached.](#)  
*The mission of translational research involves difficult tasks to be...*25th September, 2009  
Center of Surgical and Molecular Tumor Pathology, National Institute of- Pol Arch Med Wewn. 2009 Sep;119(9):586-94.
- [Ribavirin acts via multiple pathways in inhibition of leukemic cell proliferation.](#)  
*The aim of this study was to elucidate the anticancer activity of...*25th September, 2009

National Institute of Oncology, Department of Molecular Genetics, H-1122- Anticancer Res. 2009 Jun;29(6):1971-80.

- [Spatial analysis of breast and cervical cancer incidence in small geographical areas in Cuba, 1999-2003.](#)  
*According to the data from the National Cancer Registry, breast and...* 16th September, 2009  
Section of Data Management and Biostatistics, Clinical Trials Department,- Eur J Cancer Prev. 2009 Sep;18(5):395-403. ([DOI Direct Link](#))
- [Small cell carcinoma of the urinary bladder: a case report and review of the literature.](#)  
*Small cell carcinoma of the bladder (SCCB) is extremely rare. In this...* 2nd September, 2009  
Department of Medical Oncology, National Institute of Oncology, Rabat,- J Cancer Res Ther. 2009 Apr-Jun;5(2):133-6. ([DOI Direct Link](#))
- [A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer.](#)  
*Vandetanib (ZACTIMA) is a once-daily oral anticancer drug that selectively...* 7th August, 2009  
National Institute- Cancer Biother Radiopharm. 2009 Apr;24(2):175-80. ([DOI Direct Link](#))
- [Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study.](#)  
*BACKGROUND: Aggressive non-melanoma skin cancer (deeply infiltrating,...* 1st August, 2009  
National Institute of Oncology and Radiobiology, Havana, Cuba.- BMC Cancer. 2009 Jul 30;9:262. ([DOI Direct Link](#))
- [Outcome of recurrent and metastatic small cell carcinoma of the bladder.](#)  
*BACKGROUND: Bladder small cell carcinoma is an uncommon tumour. Through a...* 31st July, 2009  
Department of Medical Oncology, National Institute of Oncology, Rabat,- BMC Urol. 2009 Jun 6;9:4. ([DOI Direct Link](#))
- [Small cell cancer of the bladder: pathology, diagnosis, treatment and prognosis.](#)  
*Small cell carcinoma of the bladder (SCCB) is rare, highly aggressive and...* 25th July, 2009  
Department of medical oncology, national institute of oncology- Bull Cancer. 2009 Jun;96(6):E30-44. ([DOI Direct Link](#))
- [Metastatic basal cell carcinoma to the bone and bone marrow.](#)  
*BACKGROUND: Basal cell carcinoma (BCC) is the most common carcinoma in the...* 25th July, 2009  
Department of Medical Oncology and Pathology, National Institute of- Int J Dermatol. 2009 May;48(5):481-3. ([DOI Direct Link](#))
- [Myofibroblastic sarcoma of the base of tongue. Case report and review of the literature.](#)  
*BACKGROUND: Mesenchymal malignancies with myofibroblastic differentiation...* 16th July, 2009  
Department of Radiotherapy, National Institute of Oncology, Budapest,- Strahlenther Onkol. 2009 Mar;185(3):198-201. Epub 2009 Mar 28. ([DOI Direct Link](#))
- [Concurrent chemoradiotherapy in the management of advanced nasopharyngeal carcinoma: current status.](#)  
*Nasopharyngeal carcinoma (NPC) differs from other head and neck cancers in...* 16th July, 2009  
Department of Medical Oncology, National Institute of Oncology, Rabat,- J Cancer Res Ther. 2009 Jan-Mar;5(1):3-7.
- [Concurrent chemoradiotherapy in adjuvant treatment of breast cancer.](#)  
*BACKGROUND: The optimal sequencing of chemotherapy and radiotherapy after...* 9th June, 2009  
Department of Medical Oncology, National Institute of Oncology, Rabat,- Radiat Oncol. 2009 Apr 7;4:12. ([DOI Direct Link](#))

## Press Releases on National Institute of Oncology:

<a href="#">Democratic National Committee Chairman Tim Kaine Issues Statement Praising the House of Representative's Historic Vote to Pass Health Insurance Reform</a>	8th November, 2009	Democratic National Committee	WASHINGTON, Nov. 7 /PRNewswire-USNewswire/ -- Tonight the House of Representatives passed the Affordable Health Care for America Act, landmark health reform legislation that will ensure every American
<a href="#">National Alliance for Hispanic Health President and CEO Applauds House Action, Calls on Senate to Pass Health Reform in 2009</a>	8th November, 2009	National Alliance for Hispanic Health	Nation's largest network of Hispanic health advocates committed to achieving meaningful health care reform in 2009 WASHINGTON, Nov. 7 /PRNewswire-USNewswire/ -- "Tonight the U.S. House of
<a href="#">AMA Honors Family Violence Prevention Expert</a>	7th November, 2009	American Medical Association	HOUSTON, Nov. 7 /PRNewswire-USNewswire/ -- The American Medical Association (AMA) proudly presented Lisa James, Director of Health at the Family Violence Prevention Fund, with the Citation for
<a href="#">Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results</a>	6th November, 2009	Kaiser Permanente	OAKLAND, Calif., Nov. 6 /PRNewswire/ -- Kaiser Foundation Health Plan, Inc., Kaiser Foundation Hospitals (KFHP/H), and their subsidiaries reported today a combined total operating revenue of \$10.5
<a href="#">VA Summit Frames Plan to End Veteran Homelessness</a>	6th November, 2009	National Coalition for Homeless Veterans	WASHINGTON, Nov. 6 /PRNewswire-USNewswire/ -- The U.S. Department of Veterans Affairs held a historic three-day conference in the nation's capital to signal the beginning of a new mission for the

## BioNews Results for National Institute of Oncology



- [Carmel Pharma Introduces PhaSeal? Secondary Set \(C60\)](#)  
*Entrepreneur.com: Nov 2 2009 2:39AM Matching: national institute oncology*
- [Carmel Pharma Introduces PhaSeal, Secondary Set \(C60\)](#)  
*Therapeutics Daily: Nov 1 2009 1:26PM Matching: national institute oncology*
- [Carmel Pharma Introduces PhaSeal Secondary Set \(C60\)](#)

- Prudent Press Agency: Nov 1 2009 4:07PM Matching: national institute oncology*
- [Carmel Pharma Introduces PhaSeal Secondary Set \(C60\)](#)  
*PRWeb: Nov 1 2009 1:04PM Matching: national institute oncology*
  - [Carmel Pharma Introduces PhaSeal Secondary Set \(C60\)](#)  
*PR.com: Nov 1 2009 12:27PM Matching: national institute oncology*
  - [Carmel Pharma Introduces PhaSeal Secondary Set \(C60\)](#)  
*Pharmacy Choice: Nov 1 2009 10:38AM Matching: national institute oncology*
  - [Carmel Pharma Introduces PhaSeal Secondary Set \(C60\)](#)  
*PRWeb: Nov 1 2009 4:27AM Matching: national institute oncology*
  - [Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment](#)  
*Journal of Clinical Oncology: Oct 31 2009 5:51PM Matching: national institute oncology*
  - [Costs and Benefits of the National Cancer Institute Central Institutional Review Board \[Economic Analysis\]](#)  
*Journal of Clinical Oncology: Oct 31 2009 5:50PM Matching: national institute oncology*
  - [Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recu](#)  
*Journal of Clinical Oncology: Oct 31 2009 5:49PM Matching: national institute oncology*
  - [Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced](#)  
*Journal of Clinical Oncology: Oct 31 2009 5:52PM Matching: national institute oncology*
  - [Outcome of Patients Treated for Relapsed or Refractory Acute Lymphoblastic Leukemia: A Therapeutic Advances in](#)  
*Journal of Clinical Oncology: Oct 31 2009 5:49PM Matching: national institute oncology*
  - [Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients](#)  
*Journal of Clinical Oncology: Oct 31 2009 5:47PM Matching: national institute oncology*
  - [Association of Molecular Markers With Toxicity Outcomes in a Randomized Trial of Chemotherapy for Advanced Col](#)  
*Journal of Clinical Oncology: Oct 31 2009 5:51PM Matching: national institute oncology*
  - [Physician Referral for Fertility Preservation in Oncology Patients: A National Study of Practice Behaviors \[He](#)  
*Journal of Clinical Oncology: Oct 31 2009 5:48PM Matching: national institute oncology*

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

